Evidence map›Paper›PMID 40512155›Full record

ArticleCancer discovery2025

Germline-Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis.

Paola Gasperini, Alessandro Alaimo, Blerta Stringa, Yoon-Mi Chung, Yari Ciani, Francesca Lorenzin, Giulia Fracassi, Yanis Zekri, Francesco Orlando, Orsetta Quaini and 9 more

Abstract read
In one paragraph

Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Paola GasperiniDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0002-3016-9742
Alessandro AlaimoDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0002-5888-6268
Blerta StringaDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0002-2902-5979
Yoon-Mi ChungDesai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0001-9721-9444
Yari CianiDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0002-9635-2830
Francesca LorenzinDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0009-0006-5221-6059
Giulia FracassiDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0002-1947-6637
Yanis ZekriDivision of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0003-4925-4610
Francesco OrlandoDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0001-9884-9413
Orsetta QuainiDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0009-0008-3466-8988
Sebastian GregoricchioDivision of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-9209-5403
Gianluca PetrisDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0002-2420-6359
Antonio CasiniAlia Therapeutics, Trento, Italy.ORCID 0000-0001-7709-4955
Christopher E BarbieriDepartment of Urology, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0381-1947
Wilbert ZwartDivision of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-9823-7289
Anna CeresetoDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0003-4453-2597
Nima SharifiDesai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0003-1281-3474
Andrea LunardiDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0001-6218-2565
Francesca DemichelisDepartment of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.ORCID 0000-0002-8266-8631

Funding

Elucidating a novel molecular biomarker for castration-resistant prostate cancerR01CA172382 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Nima Sharifi · 2012 to 2026
$5.2M
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate CancerR01CA249279 · NCI · UNIVERSITY OF MINNESOTA · PI HALABI, SUSAN, SHARIFI, NIMA · 2021 to 2024
$2.1M
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancerR01CA236780 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHARIFI, NIMA · 2020 to 2024
$1.8M
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapyR01CA261995 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Nima Sharifi · 2022 to 2026
$1.8M
Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 19221Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 27893Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 29370Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 29926-2023Giovanni Armenise-Harvard Foundation (GAHF)National Cancer Research Institute (NCRI) R01CA172382National Cancer Research Institute (NCRI) R01CA236780National Cancer Research Institute (NCRI) R01CA249279National Cancer Research Institute (NCRI) R01CA261995NCI NIH HHS R01 CA172382NCI NIH HHS R01 CA236780NCI NIH HHS R01 CA249279NCI NIH HHS R01 CA261995Prostate Cancer Foundation (PCF) 19YOUN16
6 · The paper itself

Abstract

The biological mechanisms underlying the cooperation between germline genetic variants and somatic mutations during carcinogenesis are rarely elucidated. In this study, characterizing isogenic prostate cancer cell lines, we dissected the interplay between a germline variant at the 7p14.3 locus (rs1376350, G>A) and early recurrent prostate cancer-specific mutation in the speckle-type POZ protein (SPOP) gene across human prostate adenocarcinomas. The transcriptomes of multiple edited models pointed to GLI3 and the Hedgehog signaling pathway in a genotype-specific manner, whereas SPOP mutation and androgen receptor stimulation promote GLI3 accumulation in the full-length, transcriptionally active form. This, in turn, triggers the cell-autonomous production of steroids that prostate cancer relies on, in line with the enhanced responsiveness of SPOP-mutated prostate cancer to androgen deprivation therapy. These data demonstrate that germline variants dictate prostate cancer somatic evolution and suggest opportunities to jointly model germline-somatic relationship to help untangle the complexity of human cancer. SIGNIFICANCE: Significant heritability is observed for common cancer types worldwide. The molecular mechanisms by which inherited genetics facilitate cancer initiation might transit through its cooperation with specific somatic events that then dictate the tumor features. Through a germline-somatic tandem leading to steroid biosynthesis, we suggest a paradigm to study cancer initiation.

Indexed as

Germ-Line MutationProstatic NeoplasmsRepressor ProteinsSteroidsCell Line, TumorHumansMaleNuclear ProteinsNuclear ProteinsRepressor ProteinsSPOP protein, humanSteroids

Identifiers

PMID40512155
PMCPMC12498101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.